THERAVECTYS is a Paris-based, privately-owned, fully integrated discovery and clinical development biotech company. As a spin-off of the Pasteur Institute, the company capitalizes over 15 years of fundamental research in the field of lentiviral vectors.
THERAVECTYS has secured worldwide exclusive rights to Pasteur’s proprietary intellectual property related to the use of lentiviral vectors for human and veterinary vaccination and immunotherapy applications.